[go: up one dir, main page]

ES2075964T3 - Complejos inmunogenos, en particular iscomes. - Google Patents

Complejos inmunogenos, en particular iscomes.

Info

Publication number
ES2075964T3
ES2075964T3 ES91918619T ES91918619T ES2075964T3 ES 2075964 T3 ES2075964 T3 ES 2075964T3 ES 91918619 T ES91918619 T ES 91918619T ES 91918619 T ES91918619 T ES 91918619T ES 2075964 T3 ES2075964 T3 ES 2075964T3
Authority
ES
Spain
Prior art keywords
quil
fractions
complexes
immunological
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918619T
Other languages
English (en)
Inventor
Gideon Frank Anne Kersten
Arjen Spiekstra
Gerrit Van De Werken
Eduard Coen Beuvery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Application granted granted Critical
Publication of ES2075964T3 publication Critical patent/ES2075964T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A COMPLEJOS INMUNOGENICOS TALES COMO LAMINAS BIDIMENSIONALES QUE TIENEN ESTRUCTURA DE PANAL Y EN PARTICULAR ISCOMS TRIDIMENSIONALES, CUYOS COMPLEJOS INMUNOGENICOS ESTAN COMPUESTOS DE POR LO MENOS UN ESTEROL, UNA SAPONINA Y EN EL CASO DE ISCOMS TAMBIEN UN FOSFOLIPIDO Y TAMBIEN, OPCIONALMENTE UN ANTIGENO QUE GENERA UNA REACCION INMUNOLOGICA. LA SAPONINA USADA ES POR LO MENOS UNA DE LAS FRACCIONES QUE SE DERIVAN DEL QUIL A POR MEDIO DE CROMATOGRAFIA DE INTERACCION HIDROFOBICA Y TIENE LA DESIGNACIONES QA 1 A QA 23, TAL COMO SE MUESTRAN EN LA FIGURA POR LOS NUMEROS 1 A 23. CON PREFERENCIA LA SAPONINA USADA ES UNA O MAS DE LAS FRACCIONES DERIVADAS DEL QUIL A QUE TIENE LAS DESIGNACIONES QA 3, QA 17 Y QA 23. ASI COMO RELACIONADO CON EL COMPLEJO INMUNOLOGICO, LA INVENCION TAMBIEN SE REFIERE AL METODO ESPECIFICO DE PREPARACION DE LAS PERTINENTES FRACCIONES QUIL A, A VACUNAS QUE CONTIENEN TALES COMPLEJOS INMUNOLOGICOS Y A CONJUNTOS QUE CONTIENEN, POR UNA PARTE, UN COMPLEJO INMUNOGENICO (VACIO) Y, POR OTRA PARTE, UNA O MAS PROTEINAS O PEPTIDOS ANTIGENICOS QUE TIENEN UN FRAGMENTO HIDROFOBICO QUE PUEDE O NO HABER SIDO INTRODUCIDO SINTETICAMENTE.
ES91918619T 1990-10-23 1991-10-23 Complejos inmunogenos, en particular iscomes. Expired - Lifetime ES2075964T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9002314A NL9002314A (nl) 1990-10-23 1990-10-23 Immunogene complexen, in het bijzonder iscoms.

Publications (1)

Publication Number Publication Date
ES2075964T3 true ES2075964T3 (es) 1995-10-16

Family

ID=19857870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918619T Expired - Lifetime ES2075964T3 (es) 1990-10-23 1991-10-23 Complejos inmunogenos, en particular iscomes.

Country Status (10)

Country Link
US (1) US5620690A (es)
EP (1) EP0555276B1 (es)
AT (1) ATE127024T1 (es)
CA (1) CA2094600C (es)
DE (1) DE69112634T2 (es)
DK (1) DK0555276T3 (es)
ES (1) ES2075964T3 (es)
GR (1) GR3017778T3 (es)
NL (1) NL9002314A (es)
WO (1) WO1992006710A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010291A1 (en) * 1992-10-30 1994-05-11 Seed Capital Investment (Sci) B.V. CULTURE CELLS OF $i(QUILLAJA SP.)
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
AU1077795A (en) * 1993-09-30 1995-04-18 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE69840962D1 (de) * 1997-08-29 2009-08-20 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
ATE409495T1 (de) 2001-04-04 2008-10-15 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
WO2004030696A2 (en) * 2002-10-02 2004-04-15 Nordic Vaccine Technology A/S Composition for vaccination
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2592627C (en) * 2005-01-20 2014-02-25 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP1873522B1 (en) * 2005-04-14 2014-08-13 Panasonic Healthcare Co., Ltd. Method for determination of hemoglobin derivative, and reagent composition, assay kit, analysis device and analysis system for use in the method
CN102281892A (zh) 2009-01-13 2011-12-14 特朗斯吉有限公司 酿酒酵母线粒体核酸级分用于免疫刺激的用途
EP3311827B1 (en) * 2011-10-03 2023-01-04 Canqura Oncology Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
IL303336A (en) 2015-09-03 2023-08-01 Novavax Inc Vaccine compositions having improved stability and immunogenicity
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
CA3092984A1 (en) 2018-03-19 2019-09-26 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE3775783D1 (de) * 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins

Also Published As

Publication number Publication date
EP0555276B1 (en) 1995-08-30
EP0555276A1 (en) 1993-08-18
DE69112634D1 (de) 1995-10-05
DE69112634T2 (de) 1996-02-08
GR3017778T3 (en) 1996-01-31
ATE127024T1 (de) 1995-09-15
CA2094600C (en) 1998-12-08
WO1992006710A1 (en) 1992-04-30
CA2094600A1 (en) 1992-04-24
NL9002314A (nl) 1992-05-18
DK0555276T3 (da) 1995-09-18
US5620690A (en) 1997-04-15

Similar Documents

Publication Publication Date Title
ES2075964T3 (es) Complejos inmunogenos, en particular iscomes.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
SE8604007L (sv) Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
PT584348E (pt) Vacina genetica para virus da imunodeficiencia
DK602989A (da) Saponinadjuvans
NO991524L (no) Vaksiner
ES2138588T3 (es) Composiciones de vacunas que contienen liposomas.
ZA936629B (en) Potentiation of immunogenic response
SE8307205D0 (sv) Kemiska foreningar
HRP940279B1 (en) IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS
DE69327529D1 (de) Immunologisch mit HLA homologe HIV Protein Epitope
AR021414A1 (es) Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
NZ223980A (en) An aids-type virus vaccine comprising an antibody equivalent which recognises an epitope on a cd4 cell-marker
ES2061705T3 (es) Procedimiento de obtencion de un preparado antigenico de toxoplasma gondii y sus aplicaciones diagnosticas y profilacticas.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
ATE329615T1 (de) Borrelia burgdorferi bacterin
ES2052273T3 (es) Composicion que contiene un epitopo b de la glicoproteina que envuelve un retrovirus y un epitopo t de una proteina distinta de dicho retrovirus.
ES2056780T1 (es) Un procedimiento para el aislamiento de virus de hav.
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
GB8730022D0 (en) Babesia divergens antigen & vaccine
ECSP961731A (es) Vacunas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 555276

Country of ref document: ES